Mettler-Toledo International Inc. (0K10.L)
USD 1085.39
(2.02%)
USD 1085.39
(2.02%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 2.16 Billion USD | -0.02% |
| 2022 | 2.24 Billion USD | 6.32% |
| 2021 | 2.1 Billion USD | 20.87% |
| 2020 | 1.74 Billion USD | 3.12% |
| 2019 | 1.69 Billion USD | 3.34% |
| 2018 | 1.63 Billion USD | 6.77% |
| 2017 | 1.53 Billion USD | 10.07% |
| 2016 | 1.39 Billion USD | 4.44% |
| 2015 | 1.33 Billion USD | -1.85% |
| 2014 | 1.35 Billion USD | 5.99% |
| 2013 | 1.28 Billion USD | 3.29% |
| 2012 | 1.24 Billion USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 565.66 Million USD | 3.32% |
| 2024 Q1 | 529.9 Million USD | -0.69% |
| 2023 Q3 | 541.22 Million USD | -4.29% |
| 2023 Q1 | 528.78 Million USD | -14.1% |
| 2023 Q4 | 533.56 Million USD | -1.42% |
| 2023 Q2 | 565.5 Million USD | 6.94% |
| 2023 FY | 2.16 Billion USD | -3.24% |
| 2022 FY | 2.24 Billion USD | 6.32% |
| 2022 Q3 | 567.92 Million USD | 2.27% |
| 2022 Q2 | 555.29 Million USD | 10.4% |
| 2022 Q1 | 502.98 Million USD | -14.78% |
| 2022 Q4 | 615.59 Million USD | 8.39% |
| 2021 Q3 | 539.78 Million USD | 3.67% |
| 2021 Q4 | 590.19 Million USD | 9.34% |
| 2021 Q1 | 457.81 Million USD | -18.11% |
| 2021 Q2 | 520.68 Million USD | 13.73% |
| 2021 FY | 2.1 Billion USD | 20.87% |
| 2020 Q2 | 397.97 Million USD | 6.29% |
| 2020 Q4 | 559.04 Million USD | 19.04% |
| 2020 FY | 1.74 Billion USD | 3.12% |
| 2020 Q1 | 374.4 Million USD | -24.86% |
| 2020 Q3 | 469.6 Million USD | 18.0% |
| 2019 FY | 1.69 Billion USD | 3.34% |
| 2019 Q4 | 498.29 Million USD | 14.54% |
| 2019 Q3 | 435.05 Million USD | 3.7% |
| 2019 Q2 | 419.53 Million USD | 8.04% |
| 2019 Q1 | 388.31 Million USD | -18.69% |
| 2018 Q1 | 374.93 Million USD | -17.74% |
| 2018 Q3 | 419.25 Million USD | 1.61% |
| 2018 FY | 1.63 Billion USD | 6.77% |
| 2018 Q2 | 412.62 Million USD | 10.05% |
| 2018 Q4 | 477.56 Million USD | 13.91% |
| 2017 FY | 1.53 Billion USD | 10.07% |
| 2017 Q2 | 375.61 Million USD | 9.38% |
| 2017 Q4 | 455.77 Million USD | 13.67% |
| 2017 Q3 | 400.97 Million USD | 6.75% |
| 2017 Q1 | 343.38 Million USD | -17.97% |
| 2016 Q4 | 418.61 Million USD | 13.29% |
| 2016 FY | 1.39 Billion USD | 4.44% |
| 2016 Q3 | 369.49 Million USD | 6.31% |
| 2016 Q2 | 347.57 Million USD | 15.89% |
| 2016 Q1 | 299.9 Million USD | -23.25% |
| 2015 Q2 | 322.91 Million USD | 8.07% |
| 2015 Q3 | 339.52 Million USD | 5.15% |
| 2015 FY | 1.33 Billion USD | -1.85% |
| 2015 Q1 | 298.8 Million USD | -24.23% |
| 2015 Q4 | 390.74 Million USD | 15.09% |
| 2014 Q4 | 394.38 Million USD | 14.8% |
| 2014 FY | 1.35 Billion USD | 5.99% |
| 2014 Q1 | 292.64 Million USD | -22.04% |
| 2014 Q2 | 328.17 Million USD | 12.14% |
| 2014 Q3 | 343.55 Million USD | 4.68% |
| 2013 Q2 | 308.84 Million USD | 10.63% |
| 2013 Q3 | 318.57 Million USD | 3.15% |
| 2013 Q4 | 375.35 Million USD | 17.82% |
| 2013 FY | 1.28 Billion USD | 3.29% |
| 2013 Q1 | 279.15 Million USD | -21.76% |
| 2012 FY | 1.24 Billion USD | 0.0% |
| 2012 Q4 | 356.78 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Editas Medicine, Inc. | -99.52 Million USD | 2279.36% |
| Dynavax Technologies Corporation | 182.11 Million USD | -1091.033% |
| Cara Therapeutics, Inc. | 14.79 Million USD | -14561.843% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 91.822% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | -314.149% |
| Perrigo Company plc | 1.68 Billion USD | -29.081% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 693094.569% |
| Illumina, Inc. | 2.74 Billion USD | 20.952% |
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 85.752% |
| Nektar Therapeutics | 53.47 Million USD | -3956.01% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 22774.817% |
| IQVIA Holdings Inc. | 5.23 Billion USD | 58.598% |
| Heron Therapeutics, Inc. | 10.04 Million USD | -21500.01% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 11111.082% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | -13.9% |
| Waters Corporation | 1.76 Billion USD | -23.159% |
| Biogen Inc. | 7.3 Billion USD | 70.296% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 4885.6% |
| Adicet Bio, Inc. | -6.09 Million USD | 35670.236% |
| Evolus, Inc. | 140.52 Million USD | -1443.539% |
| bluebird bio, Inc. | -4.03 Million USD | 53923.151% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 2645.382% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -2868.608% |
| FibroGen, Inc. | 128.9 Million USD | -1582.704% |
| Agilent Technologies, Inc. | 3.46 Billion USD | 37.4% |
| Homology Medicines, Inc. | -7.22 Million USD | 30105.16% |
| Geron Corporation | -123.5 Million USD | 1856.292% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | -42.901% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 7059.371% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | -499.142% |
| Myriad Genetics, Inc. | 476.4 Million USD | -355.305% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 80.807% |
| OPKO Health, Inc. | 318.12 Million USD | -581.826% |
| Viking Therapeutics, Inc. | -292 Thousand USD | 742933.219% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 643.908% |
| Zoetis Inc. | 5.83 Billion USD | 62.82% |
| Abeona Therapeutics Inc. | 302 Thousand USD | -718136.093% |
| Exelixis, Inc. | 1.75 Billion USD | -23.407% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 74.799% |
| uniQure N.V. | 2.21 Million USD | -97826.546% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 715965.677% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | -787.019% |
| Verastem, Inc. | -62 Thousand USD | 3498604.839% |
| Imunon, Inc. | -720 Thousand USD | 301358.047% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | -178.617% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | -98.453% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | -17.412% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | -355.789% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | -240.572% |
| TG Therapeutics, Inc. | 219.1 Million USD | -889.956% |
| Blueprint Medicines Corporation | 236.58 Million USD | -816.83% |
| Insmed Incorporated | 239.63 Million USD | -805.157% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | -12424.239% |
| Incyte Corporation | 3.44 Billion USD | 36.957% |
| Emergent BioSolutions Inc. | 343.9 Million USD | -530.728% |